Results 181 to 190 of about 237,895 (332)

Deciphering the catalytic and pharmacological mechanisms of Coptis chinensis herbzymes to renovate intestinal microenvironment for colitis alleviation

BMEMat, EarlyView.
The synthesized CCzymes possess both antioxidant enzyme activity and pharmacological properties inherent to Coptis chinensis. By their antioxidant enzyme activity, CCzymes can attenuate oxidative stress within the inflammatory region of ulcerative colitis (UC), while their pharmacological activity acts on macrophage polarization and the intestinal ...
Zhichao Deng, Can Li, Yujie Zhang, Yuanyuan Zhu, Chenxi Xu, Bowen Gao, Mingxin Zhang, Martina H. Stenzel, Kelong Fan, Mingzhen Zhang, Yanyan Jiang   +10 more
wiley   +1 more source

Integrative in vitro and in silico evaluation of HSP60-derived peptides as immunomodulators of the TLR4/MD-2 complex. [PDF]

Sci Rep
Vila-Casahonda RG, Lozano-Aponte J, Fragoso-Medina JA, Zúñiga-Ramos JA, García N, Guerrero-Beltrán CE.   +5 more
europepmc   +1 more source

Nanomaterial‐based immune therapeutic strategies in neurodegenerative diseases

BMEMat, EarlyView.
This review highlights the immunomodulatory potential of nanomaterials (NMs) in treating neurodegenerative diseases (NDs). It focuses on their roles in regulating innate and adaptive immune responses to maintain immune homeostasis. By providing insights into these mechanisms, the review lays the groundwork for innovative NMs therapeutic strategies to ...
Xinru Zhou, Jia Liu, Shulin Lai, Suhan Yin, Bingmin Luo, Longquan Shao, Yiyuan Kang   +6 more
wiley   +1 more source

Current update on toll-like receptors and prostate cancer: a decade of progress and emerging insights. [PDF]

Front Immunol
Janjirala J, Blanton M, Ramos KS, Zhang D.   +3 more
europepmc   +1 more source

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

BMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao, Rui Qu, Zan Dai, Xiqun Jiang, Xu Zhen   +4 more
wiley   +1 more source

A Novel TLR4 Inhibitor DB03476 Rescued Renal Inflammation in Acute Kidney Injury Model. [PDF]

Int J Mol Sci
Zhang YF, Ma YX, Wei SJ, Yang B, Ji YH, Qi ZX, Shi XY, Zhang LL, Fan XZ, Yang XJ.   +9 more
europepmc   +1 more source

Synthetic Cathepsin B Sensitive Adjuvant‐Peptide Conjugates to Target Intracellular Toll‐Like Receptors 7 and 8

ChemistryEurope, EarlyView.
Cathepsin B‐sensitive peptide–adjuvant conjugates are designed, synthesized, and evaluated to deliver an antigenic peptid and an adjuvant targeting Toll‐like receptors 7 and 8 (TLR7/8) to antigen presenting cells. The adjuvant is released by cathepsin B resulting in antigen presentation and TLR mediated T cell activation.
Marjolein M. E. Isendoorn, Giulia Castello, Nico J. Meeuwenoord, Martijn Verdoes, Jeroen D. C. Codée, Ferry Ossendorp, Dmitri V. Filippov   +6 more
wiley   +1 more source

Retraction: Impact of miR-223-3p and miR-2909 on inflammatory factors IL-6, IL-1ß, and TNF-α, and the TLR4/TLR2/NF-κB/STAT3 signaling pathway induced by lipopolysaccharide in human adipose stem cells. [PDF]

PLoS One
PLOS One Editors.
europepmc   +1 more source

CaMKIIα expression in a mouse model of NMDAR hypofunction schizophrenia: Putative roles for IGF-1R and TLR4

, 2017
Olalekan M. Ogundele, Charles C. Lee
openalex   +2 more sources

mRNA-103 inhibition attenuates autophagy and inflammation in myocardial infarction by regulating the TLR4 pathway

, 2020
Fan Li, Xiaohui Ma, Tong Liu, Yang Wang, Xin Xie, Xin Yi, Kang Cheng   +6 more
openalex   +1 more source